Jazz Pharmaceuticals has updated that its lung cancer drug, Zepzelca, failed to meet the goal of improving overall survival in a late-stage study. The company has shared the trial results with U.S….
Category: Lung Cancer Drugs
Get an ideas about the lung cancer treatment drugs, here we provide only information about drugs not to advice them to take without proper doctor guideline. For information about lung cancer drugs browse.
Merck-Kelun Lung Cancer Drug Outperforms Keytruda in Trial
According to Phase 3 study results, Merck-Kelun combo can reduce the risk of tumor progression by 65% in patients with lung cancer. The study has been conducted in China and is the…
India’s First 7-Minute NSCLC Shot Launched Costing ₹3.7 Lakh Per Dose
India has taken a major step towards lung cancer treatment with launch of a new seven-minute NSCLC injection. Roche Pharma India has introduced a new drug called Tecentriq and is designed to…
Markey Cancer Center Treats First US Patient with Alveltamig for Small Cell Lung Cancer
The University of Kentucky Markey Cancer Center has treated the first patient in US with a new immunotherapy for lung cancer. UK Markey Cancer Center becomes the first site in the country…
Sevabertinib Receive Accelerated Approval by FDA for Non-Squamous NSCLC
Lung cancer is one of the deadly disease responsible for many deaths all around the world. US Food and Drug Administration (FDA) has granted accelerated approval to Sevabertinib (Hyrnuo Bayer HealthCare Pharmaceuticals…
FDA Grants Breakthrough Therapy to Olomorasib to Treat Lung Cancer
Eli Lilly and Company has announced that US Food and Drug Administration (FDA) has granted breakthrough therapy designation to olomorasib, in combination with anti-PD1 therapy Keytruda for first-line treatment of patients with…
FDA Approves Hernexeos for HER2-Mutant Advanced Lung Cancer
For the first time, FDA has given approval of an oral treatment of patients with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have human epidermal growth factor receptor 2…
High-Dose Aumoltertinib for Untreated EGFR- Variant NSCLC
Aumoltertinib is a third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and has achieved potent efficacy for advanced EGFR-mutated non-small cell lung cancer patients. Phase 2 non-randomized clinical trial was conducted at…